- Home
- Companies
- Immudex ApS
- Products
- Dextramer - CMV Kit - In Vitro ...
Dextramer - CMV Kit - In Vitro Diagnostics
Transplant patients are particularly susceptible to high morbidity and mortality from cytomegalovirus (CMV) infection due to suppression of cell-mediated immunity following transplant. With worldwide infection incidences of 60 to 80%, carefully monitoring post-transplant immune reconstitution of CMV-specific CD8+ T cells is essential for appropriate prophylactic or preemptive treatment1 while balancing the costs and potential toxicity (e.g., nephrotoxicity, peripheral blood cytopenia) associated with antiviral drugs.
Delayed recovery of CMV-specific T cells is associated with recurrent CMV infection and disease2-5. Several clinical trials have demonstrated the value of quantifying CMV-specific CD8+ T cells as a predictor of immune resistance to CMV after hematopoietic stem cell transplantation (HSCT).
Such a tool is especially useful to avoid unnecessary antiviral treatment of patients with a viral load who would never progress to CMV disease because they have sufficient T-cell immunity to effectively control the virus.
The Dextramer® CMV Kit (IVD) is designed to enumerate CMV-specific CD8+ T cells in whole blood by flow cytometry6. In fact, the Dextramer® CMV Kit (IVD) is indicated in conjunction with other laboratory and clinical findings to assess CMV-specific immune status and risk of CMV reactivation in adult HSCT recipients following immunosuppression7–8.
The Dextramer® CMV Kit (IVD) cannot be used for measuring CMV infection or disease.
